HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a price target of $90.
August 15, 2024 | 10:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Denali Therapeutics and maintained a price target of $90.
The reiteration of a Buy rating and a high price target of $90 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100